← all works
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Diabetes Treatment and Management
- Field
- Medicine
- Canadian institutions
- Lunenfeld-Tanenbaum Research InstituteUniversity of TorontoMount Sinai Hospital
- Funders
- Deutsche Diabetes GesellschaftCanada Research ChairsJuvenile Diabetes Research Foundation CanadaCanadian Diabetes AssociationDeutsche ForschungsgemeinschaftEli Lilly and Company
- Keywords
- VildagliptinIncretinExenatideLiraglutideSitagliptinMedicineType 2 diabetesInternal medicineEndocrinologyGlucagon-like peptide-1Dipeptidyl peptidase-4PharmacologyGlucagon-like peptide 1 receptorGastric emptyingDiabetes mellitusReceptorAgonist
- Has abstract in OpenAlex
- no